Comparison of Brain Atrophy Rates, Cognition, and Patient-Reported Outcomes in MS Patients Using Long-term Fingolimod and Glatiramer Acetate

Exclusion Criteria

• •Suffering from comorbidities that could confound the MRI outcomes or are (relative) contraindicated to receive treatment with fingolimod such as:
• •* diabetes,
• •* myocardial infarction,
• •* unstable angina,
• •* transient ischemic attack,
• •* decompensated heart failure,
• •* history of Mobitz Type II 2nd or 3rd degree atrioventricular block,
• •* sick sinus syndrome,
• •* history of stroke,
• •* history of traumatic brain injury,
• •* history of encephalitis,
• •* dementia (not related to MS).
• •Systemic steroid used (oral or IV) within 30 days of the baseline visit.
• •Ever treated with chemotherapy.
• •Ever having undergone cranial radiation, or intracranial surgery.
• •Unable to tolerate an MRI scan.
• •Is pregnant or breastfeeding or planning on pregnancy during the study period.
• •Is decisionally challenged, illiterate or blind
• •Is non-English speaking (as the PRO instruments are only validated in English)